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Friml, J., Vieten, A., Sauer, M., Weijers, D., Schwarz, H., Hamann,and animal development. They performed a screen of
T., Offringa, R., and Ju¨rgens, G. (2003). Nature 426, 147–153.Arabidopsis embryos for mutations that cause distinc-
Lukowitz, W., Mayer, U., and Ju¨rgens, G. (1996). Cell 84, 61–71.tive changes in the pattern of embryonic cell divisions.
Lukowitz, W., Roeder, A., Parmenter, D., and Somerville, C. (2004).Embryogenesis in Arabidopsis begins with an asymmet-
Cell 116, this issue, 109–119.ric division of the zygote resulting in a small cell on top
Mayer, U., Torres Ruiz, R.A., Berleth, T., Misera, S., and Ju¨rgens,and a much larger cell beneath it. The smaller cell will
G. (1991). Nature 353, 402–407.develop into the embryo, while most of the larger cell
Shevell, D.E., Leu, W.-M., Gillmor, C.S., Xia, G., Feldmann, K.A., andbecomes an extra-embryonic structure called the sus-
Chua, N.-H. (1994). Cell 77 1051–1062.pensor. There is a parallel here to the early divisions of
the mammalian embryo in which the inner cells form the
proembryo and the outer cells will form the placenta.
In the yoda mutant, the lower cell fails to form a sus-
pensor. Instead the cells divide in a fashion resembling Old Drugs, New Tricks:those that normally form an embryo. Markers for sus-
Using Genetically Sensitized Yeastpensor cell fate are absent in these cells, while the upper
cell appears to divide normally. This suggests that the to Reveal Drug Targets
YODA gene product plays a key role in specifying the
developmental pathway that the lower cell takes after
the first embryonic division.
The big news is that YODA encodes a kinase of the
A study in this issue of Cell illustrates the power ofMAPKK family. In fact, it is the first gene shown to play
applying genomic approaches with model systems toa role in early plant embryogenesis that encodes either
characterize the biological activity of small moleculesa signaling component (unless you count auxin trans-
and to identify their cellular targets, which can clarifyporters as signaling components) or a transcription fac-
the mode of action of human therapeutics.tor. That it is actually acting as a kinase was shown
by mutation of the putative catalytic domain and the
generation of dominant-negative forms based on its Although the term chemical genetics is a relatively re-
likely structure. Constitutive expression of YODA results cent invention, the underlying principles of the approach
in an embryo that looks like a large suspensor, strongly stem from the work of 19th century chemists who under-
supporting the idea that YODA is a key developmental took the first phenotype-based assays and established
switch. that small molecules have biological activity exerted
What is the impact of the discovery of a kinase playing through interactions with specific proteins in the cell
a central role in early plant embryogenesis? In animals, (Stockwell, 2000). A “forward” chemical genetic screen
early specification events are controlled by an interplay mirrors the powerful genetic screening approaches
between signaling molecules and transcription factors. used in model organisms to explore gene function and
Presumably, downstream of YODA there are transcrip- involves testing small molecule libraries in cell-based
tion factors and upstream there is a receptor and a assays to discover compounds that elicit a revealing
signaling cascade. As the pathway is elucidated, it may phenotypic change. That this type of screen might be
reveal a conserved cassette of molecular players, as is an effective means of identifying drug targets derives
the case with innate immunity in plants and animals. from the concept that bioactive compounds can act
Similarities have already been found later in embryogen- as mimetics of genetic mutation (Giaever et al., 1999;
esis when various transcription factors, including those Hartwell et al., 1997). In other words, the inactivation of
containing homeodomains, play important roles in pat- a specific protein by a drug is conceptually equivalent
terning both in plants and animals. to mutational perturbation of the corresponding gene
There are only two successful attempts by evolution and, conversely, a mutation might be viewed as an “ide-
to make multicellular organisms. In both cases, the same alized” drug. Now, in an important application of this
basic problems had to be solved: how to get cells to concept, Lum et al. (2004 [this issue of Cell]) have used
divide so that the daughters are different, how to inte- the genome-wide set of budding yeast deletion mutants
grate the functions of cells to form tissues, how to com- as a tool for deciphering the targets for a number of
municate from one tissue to another. As we learn more different compounds with diverse chemical structures
about plant and animal development and compare how and therapeutic relevance.
components are used and reused for similar or different Chemical “space,” measured in terms of number and
results, we discover the logic behind the process. variety of molecules, is extensive: the Merck Index
alone, which lists commonly used chemicals in health,
Philip N. Benfey agriculture, industry, and laboratory science, encom-
Biology Department passes over 10,000 diverse compounds. The potential
Duke University for expanding our understanding of compound activity
Durham, North Carolina 27708 is huge; only a few percent of human gene products are
now used as targets for therapeutics. Comprehensive
Selected Reading characterization of chemical activities is particularly im-
portant for understanding primary drug action, drug sideGeldner, N., Anders, N., Wolters, H., Keicher, J., Kornberger, W.,
effects, and chemical toxicity. Moreover, chemicals withMuller, P., Delbarre, A., Ueda, T., Nakano, A., and Ju¨rgens, G. (2003).
Cell 112, 219–230. specific known targets can provide an inroad into the
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Figure 1. Theory and Barcode Methodology of Drug-Induced Haploinsufficiency in Yeast
(A) Concept of induced haploinsufficiency. It takes less drug to inhibit the protein target molecules within a heterozygous diploid cell that has
only one copy of the gene encoding the drug target, than within a wild-type cell. Consequently, heterozygous diploids are hypersensitive to
the drug.
(B) Protocol for competitive growth assay using tagged heterozygous Saccharomyces cerevisiae strains. Step 1: grow the heterozygous yeast
deletion mutant set in the presence and absence of a drug. Step 2: prepare genomic DNA from resultant yeast populations and PCR amplify
the barcode oligos, labeled with a fluorescent dye. Step 3: hybridize the labeled barcodes to a microarray and identify mutants that fail to
grow in the presence of the drug.
biological characterization of the targets and path- gene product to block glycosylation, using a small test
population of yeast strains (Giaever et al., 1999). Lumways affected.
Determining the precise molecular target of a chemi- et al (2004 [this issue of Cell]) illustrate that the method
is generally extensible through analysis of 78 differentcal inhibitor has proven to be difficult in many cases.
The conventional approach is affinity chromatography, compounds, most of which are relevant clinically or agri-
culturally, and a pool of 3503 yeast strains. Remarkably,which requires the molecule to be chemically modified
and to have a sufficiently high binding affinity such that 56 of the compounds yielded a few, interpretable genetic
“hits”; 18 drugs produced no drug-specific fitness pro-a protein target can be purified and identified by mass
spectrometry. More recent variants include yeast “three- file while the remaining four caused widespread effects.
A subset of 20 compounds with well-characterizedhybrid” systems, phage display, and protein microarrays
(Mayer, 2003). The haploinsufficiency profiling method modes-of-action was included in the study and Lum et
al (2004 [this issue of Cell]) correctly identified targetsused by Lum et al. (2004 [this issue of Cell]) exploits an
in vivo assay that can be performed with an unmodified for 7, while genes encoding components of the known
target pathways were revealed in several other cases.drug (Giaever et al., 1999). This method takes advantage
of the fact that lowering the dosage of a gene encoding A number of new candidate drug targets were also dis-
covered. For example, the yeast ERG7 gene encodesa drug target from two copies, as in a wild-type diploid
cell, to one copy, as in a heterozygous diploid, often lanosterol synthase, a highly conserved enzyme in-
volved in sterol biosynthesis. Yeast heterozygous forconfers hypersensitivity of the pertinent heterozygote
strain to the drug (Figure 1A). During the construction deletion of ERG7 showed hypersensitivity to molsidom-
ine, a potent vasodilator prescribed for treatment ofof the yeast deletion alleles, unique oligonucleotides
flanked by common PCR primer sites, termed molecular angina. Lum et al. (2004 [this issue of Cell]) showed that
purified lanosterol synthase was inhibited in vitro bybarcodes, were introduced on either side of the drug-
resistant marker that replaced the deleted gene. PCR SIN-1, the first metabolic derivative of molsidomine. This
finding may explain the observation that molsidomineamplification of the barcodes allows the presence of all
mutants to be monitored simultaneously with a micro- treatment lowers cholesterol levels in both rats and
humans.array-based detection system. In the haploinsufficiency
profiling method, a pool of heterozygous deletion mu- In an independent study, Giaever et al. (2004) exam-
ined a comprehensive set of 5916 heterozygous strainstants is grown in the presence of the drug of interest
and the molecular barcodes associated with each of the for sensitivity to 10 diverse compounds. In an intriguing
twist, Giaever et al. (2004) noticed that a similar set ofdeletion mutants are used to quantitate abundance of
the strains over successive time points. Heterozygotes heterozygous diploid strains was hypersensitive to three
seemingly disparate drugs: alverine citrate, a musclethat show hypersensitivity to the drug are cleared from
the drug-treated population and identify genes encoding relaxant; fenpropimorph, an antifungal; and dyclonine,
an anesthetic. This observation prompted a closer ex-candidate drug target proteins (Figure 1B).
The proof-of-concept behind parallel analysis of haplo- amination of these drugs and revealed that they shared
a common core chemical structure. Thus, haploinsuffi-insufficiency profiling was previously demonstrated for
tunicamycin, a drug that specifically inhibits the ALG7 ciency profiling clustered three therapeutically distinct
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compounds, suggesting that analysis of a compendium The Lum et al. (2004 [this issue of Cell]) study and other
of profiles may reveal many new structure-activity rela- recent reports illustrate that the path from sequence
tionships. and functional analysis to direct applications is not nec-
Both studies expose similar limitations of the haplo- essarily long—at least in yeast, which easily ranks
insufficiency profiling approach. For example, each group among man’s best friends.
studied 5-flourouracil (5FU), which is an antimetabolite
used in cancer treatment and is thought to inhibit thymi- Tim Hughes,1,2 Brenda Andrews,1
dylate synthase, but neither group identified a deletion and Charles Boone1,2*
mutant of thymidylate synthase in their haploinsuffi- 1Department of Medical Genetics and Microbiology
ciency profile. Although the simple interpretation is that 2 Banting and Best Department of Medical Research
that thymidylate synthase levels are not affected by University of Toronto
haploinsufficiency, both groups identified a large set of Toronto, Ontario
genes involved in ribosomal RNA processing, consistent M5G 1L6
with evidence suggesting that the antiproliferative ef- Canada
fects of 5FU may result from inhibition of RNA metabo-
lism. Giaever et al. (2004) suggest that 5FU may be Selected Reading
misincorporated into RNA, leading to impairment of es-
Conklin, D.S. (2003). Chembiochem 4, 1033–1039.sential RNA processing functions, whereas Lum et al.
Giaever, G., Flaherty, P., Kumm, J., Proctor, M., Jaramillo, D.F., Chu,(2004 [this issue of Cell]) suggest that 5FU may inhibit
A.M., Jordan, M.I., Arkin, A.P., and David, R.W. (2004). Proc. Natl.cell growth through perturbation of rRNA processing by
Acad. Sci. USA, in press.the exosome complex. In any case, the yeast experi-
Giaever, G., Shoemaker, D.D., Jones, T.W., Liang, H., Winzeler, E.A.,ments ought to provoke additional experiments into the
Astromoff, A., and Davis, R.W. (1999). Nat. Genet. 21, 278–283.mechanism of action of 5FU with an eye to new thera-
Hartwell, L.H., Szankasi, R., Roberts, C.J., Murray, A.W., and Friend,peutic options in cancer treatment.
S.H. (1997). Science 278, 1064–1068.
The failure to identify direct drug targets by haplo-
Hughes, T.R., Marton, M.J., Jones, A.R., Roberts, C.J., Stoughton,insufficiency profiling may reflect the complex genetic
R., Armour, C.D., Bennett, H.A., Coffey, E., Dai, H., He, Y., et al.
landscape of the cell that is plagued with redundant (2000). Cell 102, 109–126.
pathways; the application of other chemical genomics Lum, P.Y., Armour, C.D., Stepaniants, S.B., Cavet, G., Wolf, M.K.,
approaches will help biologists elucidate drug activity Butler, J.S., Hinshaw, J.C., Garnier, P., Prestwich, G.D., Leonardson,
in the context of networks of interacting gene products. A., et al. (2003). Cell 116, this issue, 121–137.
For example, a compendium of genome-wide maps of Mayer, T.U. (2003). Trends Cell Biol. 13, 270–277.
the fitness defects associated with yeast double mu- Parsons, A.B., Brost, R.L., Ding, H., Li, Z., Zhang, C., Sheikh, B.,
tants provides a key for interpreting the chemical sensi- Brown, G.W., Kane, P.M., Hughes, T.R., and Boone, C. (2003). Nature
Biotechnology. Published online December 7, 2003.tivity profiles of haploid yeast deletion mutants and has
Stockwell, B.R. (2000). Nat. Rev. Genet. 1, 116–125.the potential to identify pathways and targets affected
by drug treatment (Parsons et al., 2003). Methods such Zhu, H., Bilgin, M., and Snyder, M. (2003). Annu. Rev. Biochem.
72, 783–812.as gene expression profiling can provide a more general
picture of the effect of the drug in vivo, and may indicate
the target pathway(s), particularly when combined with
fitness profiling results (Hughes et al., 2000).
A major challenge now is to extend these chemical
genomics approaches to more complex cells and organ-
isms. In theory, the availability of whole genome se-
quences means that comprehensive target-based screens
can be performed against all proteins from a chosen
organism. For example, protein chips may provide a
practical approach to identification of primary and sec-
ondary drug targets (Zhu et al., 2003); while their general-
ity remains unproven, protein chips can almost certainly
be directly scaled to mammalian genomes. Recent ad-
vances in the application of RNAi technology create the
potential to use retroviral vectors to establish a popula-
tion of mammalian cells harboring integrated RNAi con-
structs that, like the yeast deletion mutants, are identi-
fied by oligonucleotide bar codes and are thus knocked
down for potential drug targets and can be utilized for
drug-sensitivity profiling (Conklin, 2003).
An ultimate goal of functional genomics is to fully
utilize gene information to benefit the human condition.
Reevaluation of existing medical practice provides at
least 8-fold estimated returns on research expenditure
(NIH publication No. 93-3109) and identifying off-label
uses for approved drugs is one of the fastest mecha-
nisms for placing new pharmaceutical tools in the clinic.
